Kalaris Therapeutics, Inc. Common Stock KLRS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $34.43M-64.9% | $98.05M+131% | $42.39M-52.1% | $88.43M-12.4% | $100.97M+6,060% | ||
| $62.79M+215% | $19.93M-42.4% | $34.61M— | —— | —— | ||
| $98.47M-17.1% | $118.81M+52.0% | $78.18M-14.7% | $91.65M-10.3% | $102.18M+3,821% | ||
| $109.81M-9.8% | $121.74M+50.0% | $81.18M-12.6% | $92.84M-9.9% | $103.09M+1,573% | ||
| $905K-29.4% | $1.28M+159% | $494K-86.6% | $3.68M+55.0% | $2.37M+52.2% | ||
| $8.08M-16.8% | $9.71M+60.2% | $6.07M-20.7% | $7.65M+7.1% | $7.14M-71.1% | ||
| $41.25M-3.9% | $42.92M+9.2% | $39.31M-1.0% | $39.73M+1.3% | $39.22M-30.9% | ||
| $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | $2K— | ||
| -$170.86M-6.8% | -$160M-6.7% | -$150M-8.6% | -$138.11M-9.0% | -$126.76M-8.7% | ||
| $68.56M-13.0% | $78.81M+88.3% | $41.87M-21.2% | $53.12M-16.8% | $63.87M+166% | ||
| $109.81M-9.8% | $121.74M+50.0% | $81.18M-12.6% | $92.84M-9.9% | $103.09M+1,573% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kalaris Therapeutics, Inc. Common Stock's total assets?
- Kalaris Therapeutics, Inc. Common Stock (KLRS) holds $109.8M in total assets, up 6.5% year over year.
- How much debt does Kalaris Therapeutics, Inc. Common Stock have?
- Kalaris Therapeutics, Inc. Common Stock carries $1.4M in total debt against $68.6M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Kalaris Therapeutics, Inc. Common Stock have?
- Kalaris Therapeutics, Inc. Common Stock holds $34.4M in cash and equivalents.
- Can Kalaris Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 12.19 — current assets exceed current liabilities.
- Where does Kalaris Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.